Charter Life Sciences





	XLumena Spots $6M For Ultrasound Devices June 4, 2008 Mirabilis Completes First Human Trial of Non-Invasive Treatment for Uterine Fibroids APRIL 28, 2008 Astellas and CoMentis Sign Agreement to Collaborate on the Research, Development and Commercialization of Beta-Secretase Inhibitors APRIL 25, 2008 EnteroMedics Announces Planned Expansion of EMPOWER Pivotal Study for Obesity to 300 Patients February 26, 2008 KFx Medical Corporation Appoints Matt Meyer as its Vice President Marketing February 20, 2008 EnteroMedics(TM) Announces Nine-Month Clinical Results on Its VBLOC-RF2 Feasibility Study for Obesity Therapy January 8, 2008 EnteroMedics(TM) Announces Pivotal Clinical Study of its VBLOC(TM) Therapy for Obesity January 7, 2008 CoMentis Announces Proof-of-Activity-Data from its Phase I Study of Disease-Modifying Alzheimer’s Disease Therapy January 7, 2008 APT Pharmaceuticals Expands Management Team NOVEMBER 19, 2007 EnteroMedics Announces Initial Public Offering NOVEMBER 14, 2007 APT Pharmaceuticals Closes New $22 Million Funding Round OCTOBER 4, 2007 JDRF Partners with CoMentis for Diabetic Macular Edema Clinical Trial SEPTEMBER 20, 2007 Mirabilis Closes $10.5 Million Series A Extension to Commercialize Non-invasive Treatment of Uterine Fibroids AUGUST 21, 2007 KFx Medical Corporation Closes $10 Million Series B Financing AUGUST 9, 2007 JDRF Partners with CoMentis for Diabetic Macular Edema Clinical Trial JUNE 18, 2007 CoMentis Announces Appointment of Martin Tolar, M.D., Ph.D., as Vice President JUNE 6, 2007 APT Acquires Exclusive Worldwide Rights to Develop and Commercialize Inhalable Cyclosporine to Prevent Lung Transplant Rejection JUNE 5, 2007 Enteromedics Files Registration Statement for Proposed Initial Public Offering MAY 25, 2007 CoMentis Initiates Phase II Clinical Trial for AMD Eye Drop Therapy APRIL 10, 2007 Athenagen Announces Name Change to CoMentis FEBRUARY 10, 2007 Athenagen’s Eye Drop Therapy for AMD is Safe and Well Tolerated in Phase I Study JANUARY 31, 2007 Athenagen Initiates Phase II Clinical Trial in Alzheimer’s Disease DECEMBER 13, 2006 Mirabilis Medica Names Mike Connolly CEO OCTOBER 3, 2006 Athenagen Raises $50 Million in Series B Financing SEPTEMBER 28, 2006 Amaranth Medical Closes $7.5 Million Series A Financing to Advance the Development of Bio-Absorbable Stents SEPTEMBER 26, 2006 Mirabilis Raises $4 Million to Commercialize Non-Invasive Treatment of Uterine Fibroids AUGUST 29, 2006 Athenagen Initiates Clinical Development of its Anti-angiogenic Eye Drop Therapy for AMD AUGUST 21, 2006 Athenagen Completes Merger with Zapaq AUGUST 14, 2006 KFx Medical Corporation Receives 510k Clearance for Knotless Tissue Fixation AUGUST 10, 2006 Athenagen Announces Publication of Results from a Proof-of-Concept Trial of its Novel alpha-7 Nicontinic Receptor Agonist in Schizophrenia JUNE 15, 2006 Athenagen Acquires Osprey Pharmaceutical Company - Adds Clinical-Stage Alzheimer's Drug Candidate to its Pipeline APRIL 13, 2006 Aradigm and APT Pharmaceuticals Initiate Phase 2 Clinical Program of Novel Treatment for Asthma MARCH 23, 2006 Athenagen Adds A. Barr Dolan to its Board of Directors FEBRUARY 22, 2006 Previous News Stories >


	Enteromedics Files Registration Statement for Proposed Initial Public Offering ST. PAUL, MN– MAY 25, 2007 EnteroMedics Inc. today announced it has filed a registration statement with the U.S. Securities and Exchange Commission relating to the proposed initial public offering of its common stock. All shares of the common stock to be sold in this offering will be offered by EnteroMedics. J.P. Morgan Securities Inc. and Morgan Stanley & Co. Incorporated are acting as joint book-running managers of this offering, with Cowen and Company, LLC and Leerink Swann & Co., Inc. acting as co-managers for the offering. The offering will be made only by means of a prospectus. When available, a copy of the preliminary prospectus related to the offering may be obtained from: J.P. Morgan Securities Inc.'s prospectus department at 4 Chase Metrotech Center, CS Level, Brooklyn, NY 11245 or by phone at (718) 242-8002, or Morgan Stanley & Co. Incorporated's prospectus department at 180 Varick, New York, NY 10014, by telephone at (866) 718-1649 or by emailing prospectus@morganstanley.com. A registration statement relating to these securities has been filed with the Securities and Exchange Commission, but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to their registration or qualification under the securities laws of any such state or jurisdiction. About EnteroMedics Inc. EnteroMedics is a development stage medical device company focused on the design and development of devices that use neuroblocking technology to treat obesity and other gastrointestinal disorders. EnteroMedics’ proprietary neuroblocking technology, VBLOC therapy, is designed to intermittently block the vagus nerve using high-frequency, low-energy, electrical impulses. EnteroMedics recently received a conditional investigational device exemption, or IDE, for its U.S. pivotal trial of its initial product for the treatment of obesity, the Maestro System.